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Background: Otomycosis is defined as an infection of the external ear canal with fungal agents. The treatment of
the disease is cleansing and drying of the external ear canal, identification and treatment of any predisposing
factors and application of topical antifungal agents. Terbinafine is used as an antifungal agent to treat otomycosis.
We proposed to investigate the probable ototoxic effect of terbinafine solution on auditory brain stem response
(ABR) and distortion product otoacoustic emission (DPOAE) when applied intratympanically in the middle ear
of rats.
Methods: The experiment was performed on 30 female Wistar albino rats. Thirty animals were divided into three
groups of 10 animals each. 1% terbinafine solution was administered to the first group (group T). The second group
(group G) was administered 40 mg/ml gentamicin solution (ototoxic control). The third group (group S) was
administered saline solution (negative control). Baseline DPOAE measurements and ABR testing from the left ears
were obtained from the animals in all groups under general anesthesia. Ear solutions were applied in the middle
ear intratympanically with a dental needle. Treatment was initiated after baseline measurements and repeated once
every two days for fifteen days.
Results: Pre and post-treatment DPOAE responses for all tested frequencies of group T and Group S showed no
statistically significant difference. However, the group G demonstrated a significant change in ABR thresholds and
DPOAE responses.
Conclusions: Terbinafine solution is a broad spectrum antifungal agent effective in the treatment of otomycosis.
The present study demonstrated that its direct administration in the middle ear of rats does not affect inner ear
function as measured by ABR and DPOAE responses.
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Otomycosis is defined as an infection of the external ear
canal with fungal agents. This includes not only the ex-
ternal ear canal but also open mastoid cavities and the
middle ear [1]. The most common etiological agents are
Candida and Aspergillus [2-4]. Infection is mainly char-
acterized by pruritus, otalgia, tinnitus and hearing loss
[1,4]. The most important point for the treatment of the
disease is cleansing and drying of the external ear canal,
identification and treatment of any predisposing factors
and application of topical antifungal agents [5,6].* Correspondence: musagit@yahoo.com
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reproduction in any medium, provided the orTerbinafine, which is from the allylamine group, is
used as an antifungal agent. There are oral and topical
formulations to treat superficial fungal infections. Al-
though terbinafine is frequently used in the treatment of
dermatophyte infections, it’s in vitro effects against Can-
dida, Aspergillus, and other pathogenic fungi agents has
been demonstrated [7,8]. Terbinafine has also shown
fungicidal activity in vitro against Aspergillus species
that lead to otomycosis [9].
The potential ototoxicity of antifungal drugs has been
reported in different experimental animal studies. Clotri-
mazole, miconazole, nystatin and tolnaftate have shown
no ototoxic effects when used as topical applications in
guinea pigs, however gentian violet has shown ototoxicd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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acetic acid, nonaqueous 2%) have also shown ototoxicity
in experimental animal studies [10]. Ciclopirox has
shown no ototoxicity when administered in the middle
ear of the guinea pig [11]. We found only one recently
published study assessing ototoxic effect of terbinafine
in the literature [12].
In our study, we aimed to assess the probable ototoxic
effect of terbinafine solutions on ABR and DPOAE when
applied intratympanically in the middle ear of rats.
Methods
Animals and groups
This study was approved by the Ethical Committee on
Animal Research of Erciyes University, Kayseri, Turkey.
The study was performed at the Experimental Animals
Studies Laboratory of Erciyes University. In this study,
30 female Wistar albino rats which approximately
weighing 200-220 g and 20 weeks of age were used. The
animals were kept in ordinary cages in a temperature
controlled room that maintained a 12-hour light/dark
cycle. The animals were supplied with free reach to food
and water. At the beginning of the study, we used an op-
erating ear microscope to examine the ear of all rats.
We cleaned debris and cerumen layout at the external
ear canal. Any rat with external or middle ear infection
was excluded from the study.
Thirty animals were divided into three groups of 10
animals each. 1% terbinafine solution was administered
to the first group (group T). The second group (group
G) was administered 40 mg/ml gentamicin solution (oto-
toxic control). The third group (group S) was adminis-
tered saline solution (negative control). 26 animals
completed the study without tympanic membrane per-
foration or any complications after drug application
(Table 1). One animal from the terbinafine group was
excluded from the study because of ear infection with
purulent drainage and three animals from the gentami-
cin and saline groups died under anesthesia during intra-
tympanic drug application.
Study design
The animals were anesthetized with ketamine (100 mg/kg
Ketalar; Pfiser Ltd., Vienna, Austria) and xylazine
(7.5 mg/kg Rompun; Bayer Ltd., Leverkusen, Germany)
given by intraperitoneal injection. Under general anesthesia,Table 1 The test groups and solutions
Group Solution Animals(n=26)
T Terbinafine solution 9
G (Ototoxic control group) Gentamycin solution 8
S (Negative control group) Saline solution 9after ear microscopic examination, pretreatment DPOAE
measurements and ABR testing were performed from the
left ears of animals in all groups. After baseline measure-
ments, an anterosuperior myringotomy was performed with
a 28-gauge dental needle and then test solutions were ap-
plied in the middle ear. The volume of the intratympanic
dose was changed between 0.03-0.05 ml according to the
volume of the individual rat’s middle ear. The treatment
was started after baseline measurements and repeated once
every two days for fifteen days. Two weeks after the last ap-
plication, DPOAE measurements and ABR testing were
obtained again and compared with the pretreatment values.
Hearing assessments
Hearing was assessed by DPOAE and ABR under gen-
eral anesthesia. All measurements were performed in a
quiet room.
DPOAE testing
Otodynamics ILO-288 Echoport equipment (Otody-
namics Ltd., London,UK) was used to measure DPOAE.
Once the probe was placed in external ear canal, the
measurements were performed. The sound stimulus that
composed DPOAE consisted of two simultaneous per-
manent pure tones at different frequencies. The stimulus
parameters L1 = L2 = 80 dB SPL with a f1/f2 ratio of
1.22 were used and the amplitude of the DPOAE signal
was recorded. DPOAE were obtained at seven different
frequencies ranging from 1000 to 8000 Hz (1001, 1501,
2002, 3003, 4004, 6006, 7996).
ABR testing
The ABR test was done on the left ear and the records
were obtained through two channels. Interacustic EP25
instrument and ABR 3A insert earphone were used to
evaluate for ABR threshold. Subdermal needle electrodes
were used to record the responses. The active electrode
was located at the vertex, in the midline of the scalp.
The reference electrodes were located in both mastoid
regions. The ground electrode was located on the gla-
bella. The ABR test was done by 1000 click stimulus at a
rate of 21 times/sc and 100 to 3000 Hz band-pass filters.
Measurements were obtained at 70 dBnHL and
decreased by increments of 20 dB until the threshold
was approached, where 10 dB increments were insti-
tuted. Repeatibility was confirmed, and the test was per-
formed twice to determinate threshold. ABR threshold
was defined on the fifth wave.
Statistical analysis
The SPSS statistical software package (SPSS, version
16.0 for windows; SPSS Inc., Chicago, Illinois, USA) was
used to perform all statistical calculations. Normal distri-
bution of the variables was tested using the One-Sample
Table 2 Auditory brainstem response thresholds and
hearing levels before and after application of various
agents
Group Pretreatment Posttreatment P
Terbinafine 21.11±7.81 28.88±13.64 0.088
Gentamycin 20.00±5.34 50.00±13.09+,& 0.001*
Saline 25.55±7.26 27.77±4.40 0.447
p (ANOVA) 0.232 0.001
* Statistical analysis was performed student’s t test p< 0.05.
+ p= 0.002 (post hoc Bonferroni) compared with group terbinafine.
&p= 0.001 (post hoc Bonferroni) compared with group saline.
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mean ± SD. Student’s t test was used to compare the
ABR thresholds and DPOAE values before and after
drug administration in each group. A one-way analysis
of variance (ANOVA) with the Bonferroni post-hoc test
was used to compare the ABR thresholds and DPOAE
values between the groups. Differences were accepted
statistically significant at a p value < 0.05.
Sample size was calculated according to the results of
the first twelve animals in the study (α: 0.05, β value
0.20, study power: 80%). We determined that at least 8
animals were required in each group. We also performed
a post hoc power analysis based on posttreatment ABR
results (effect size:1, α:0.05) that revealed the study
power as 98%.Results
Pre and post-treatment DPOAE responses for all tested
frequencies of group T and Group S showed no statisti-
cally significant difference (Figure 1A-1B). However,
post-treatment DPOAE responses were found to be
lower than pretreatment DPOAE responses in group G
and the differences were statistically significant for 3000,
4000, 6000, and 8000 Hz (Figure 1C).
Table 2 demonstrates the ABR thresholds for click
stimuli before and after drug administration in each
group. Mean ABR thresholds before and after drug ap-
plication for group T and group S showed no statisti-
cally significant difference for group T and group S.
However; following the gentamicin application a statis-
tically significant difference in ABR thresholds were
shown. Figure 2 demonstrates two examples of ABR
recordings before and after terbinafine and gentamicin
solution application.
When post-treatment ABR thresholds and DPOAE
values were compared between the groups, there were
statistically significant differences DPOAE values for all
frequencies and ABR thresholds. DPOAE values for
3000, 4000, 6000, 8000 Hz in the group G were significantly
decreased compared to other groups. ABR thresholds alsoFigure 1 Graph demonstrating DPOAE amplitudes before and after te
(C). There were no statistically significant differences in DPOAE measureme
significant differences in DPOAE measurements for saline solution (p > 0.05
and 8000 Hz of DPOAE values for gentamicin solution (p < 0.05).were significantly increased in the group G compared to
other groups (Table 2).
There was no statistically significant difference between
pretreatment and post-treatment DPOAE responses and
ABR threshold levels for groups T and S. However, the
group G demonstrated significant deterioration of ABR
thresholds and DPOAE responses, except for at 1000,
1500, and 2000 Hz.
Discussion
Topical antifungal drugs that are used to treat otomyco-
sis have many positive advantages compared to systemic
antifungal drugs. The potential advantages of topical
antifungal drugs are local application and the desired
higher tissue concentration at the affected site after ap-
plication [4]. Although there are potential advantages,
topical antifungal drugs may lead to a serious risk to the
audiovestibular system. Knowing any probable ototoxic
properties will guide clinicians in deciding on the most
appropriate drugs for treating otomycosis.
The external ear canal may be linked with the middle
ear space in many patients with otomycosis. This group
includes patients with tympanic membrane perforations,
open mastoid cavities and ventilation tubes [5]. When a
communication between the external and middle ear
space is present, any topical potentially ototoxic agent
may diffuse the inner ear through the round window
membrane (RWM). Other passage ways are the annular
ligament of the oval window, the fistula ante fenestra,rbinafine solution (A), saline solution (B) and gentamicin solution
nts for terbinafine solution (p > 0.05). There were no statistically
). There were statistically significant differences at 3000, 4000, 6000,
Figure 2 Graphs demonstrating two examples of ABR thresholds before and after terbinafine solution (A) and gentamicin solution (B).
There were no statistically significant differences in ABR thresholds before and after terbinafine solution (p > 0.05). However; ABR thresholds were
significantly increased, after gentamicin application (p < 0.05).
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represents merely a soft tissue barrier between the mid-
dle and inner ears and is accepted as the likely way for
ototoxic agents to pass from the middle ear to the inner
ear [5,14]. Studies of the RWM demonstrate that its per-
meability depends on the membrane’s morphological in-
tegrity, the molecular weight of the agents, and thepresence and duration of inflammation of the middle ear
[15,16]. Drug concentration, frequency of exposure and
duration are important factors affecting ototoxicity.
Terbinafine solution is an effective treatment modality
for mycotic infections of the external ear canal. The
mechanism of fungicidal activity of terbinafine is related
with particular inhibition of fungal squalene epoxidase
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of intracellular squalene [17]. Studies have reported that
terbinafine has in vitro effects against Candida, Aspergil-
lus and other pathogenic fungi [7,8]. It is considered ef-
fective and safe; however its probable ototoxic effect has
been unnoticed, particularly when administered topically
in the presence of tympanic membrane perforation, ven-
tilation tubes or an open mastoid cavity.
The present study, we researched the probable oto-
toxic effect of terbinafine solution on the hearing of rats
in which we applied drug for two weeks. The measure-
ments of DPOAE and ABR are commonly used to re-
search ototoxicity. DPOAE is a noninvasive method and
provides early diagnosis of cochlear damage caused by
topical solutions, which are generally detected first in
the outer hair cells [18]. Although a practical method,
DPOAE has some limitations. The effusion in the middle
ear cavity or the presence of a perforation in the tym-
panic membrane affects DPOAE responses. Also, the
size of tympanic membrane perforation affects DPOAE
responses [19]. With this in mind, we did not perforate
widely the tympanic membranes of the rats and we ap-
plied drugs in the middle ear by intratympanic (IT) in-
jection. IT injection allows a desired much higher
concentration of the drugs within the inner ear com-
pared with systemic administration [20]. IT injection
also prevents systemic side effects of drugs.
In the present study, after IT application of the terbi-
nafine solution, there was statistically neither a signifi-
cant decrease of DPOAE amplitudes nor an increase of
ABR threshold levels. The posttreatment DPOAE ampli-
tude values were less, but this decrease was not statisti-
cally significant (Figure 1A). The posttreatment mean
ABR threshold levels were higher than the pretreatment
values, but this increase was not statistically significant
(Table 2). This condition may be related to the inflam-
mation that was caused by topical administration of the
terbinafine in the middle ear cavity. The histopathologic
analyses would be beneficial which a wise undertaking as
some agents cause diffuse osteoitis and inflammation
that may only effect the ABR and DPOAE measure-
ments at an interval longer than two weeks posttreat-
ment. In the group G, we obtained a significant decrease
of DPOAE responses and also a significant increase of
mean ABR threshold levels, which once again showed
the ototoxic effect of the aminoglycoside antibiotics.
We found only one recently published study assessing
ototoxic effect of terbinafine in the literature [12]. In
that study on ototoxic effect of terbinafine by Aydın
et al. hearing was assessed by using ABR alone. In the
present study, however, we assessed ototoxicity by using
both DPOAE and ABR. Aydın et al. detected ototoxicity
by performing ABR seven days after the last administra-
tion of terbinafine. However, this ototoxic effect may betemporary and may disappear in the subsequent mea-
surements, as they mentioned as a limitation in the dis-
cussion section of their study. We repeated hearing tests
two weeks after the last administration of terbinafine.
Although we detected a decrease in the amplitudes of
DPOAE and an increase in the hearing thresholds of
ABR, the results were statistically insignificant.
The present study did not observe any ototoxic effect
of terbinafine solution. There are, however, some limita-
tions of our study that we have to mention. First, this
study demonstrated only the results of auditory tests for
assessment of ototoxicity. We did not perform any
vestibular tests for evaluating the vestibular system. Sec-
ondly, we could not perform histopathological examin-
ation to assess the effects of the terbinafine solution on
audiovestibular organs. Further studies that are com-
bined with more definitive electrophysiological, vestibu-
lar tests and histopathological examination are needed
to assess the effects of terbinafine solution on the audio-
vestibular system.
Conclusions
Terbinafine solution is a broad spectrum antifungal
agent effective in the treatment of otomycosis. The
present study demonstrated that its direct administra-
tion in the middle ear of rats does not affect inner ear
function as measured by ABR and DPOAE responses.
Terbinafine solution should be applied carefully because
its safety has not yet been demonstrated in patients who
have ventilation tubes or tympanic membrane perforation.
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